Swiss drugmaker Roche is petitioning the U.S. government in direct talks for import tariff exemptions, arguing the products it ships into the United States are offset by its exports of U.S.-made drugs and diagnostics.

Roche’s exposure to the tariffs is mostly limited to four medicines, three of which it already produces in the U.S., according to CEO Thomas Schinecker, who declined to reveal what these assets are.

The pharma giant said the investment would create more than 12,000 jobs, as it joins rival Novartis in expanding its footprint in the country amid President Trump’s tariff threats.